265 related articles for article (PubMed ID: 9842951)
1. The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention.
JAMA; 1998 Nov; 280(20):1757-63. PubMed ID: 9842951
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus.
Vijan S; Hofer TP; Hayward RA
JAMA; 2000 Feb; 283(7):889-96. PubMed ID: 10685713
[TBL] [Abstract][Full Text] [Related]
3. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis.
Hoerger TJ; Harris R; Hicks KA; Donahue K; Sorensen S; Engelgau M
Ann Intern Med; 2004 May; 140(9):689-99. PubMed ID: 15126252
[TBL] [Abstract][Full Text] [Related]
4. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
[TBL] [Abstract][Full Text] [Related]
5. Screening for type 2 diabetes: literature review and economic modelling.
Waugh N; Scotland G; McNamee P; Gillett M; Brennan A; Goyder E; Williams R; John A
Health Technol Assess; 2007 May; 11(17):iii-iv, ix-xi, 1-125. PubMed ID: 17462167
[TBL] [Abstract][Full Text] [Related]
6. Visual screening for malignant melanoma: a cost-effectiveness analysis.
Losina E; Walensky RP; Geller A; Beddingfield FC; Wolf LL; Gilchrest BA; Freedberg KA
Arch Dermatol; 2007 Jan; 143(1):21-8. PubMed ID: 17224538
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.
Dong FB; Sorensen SW; Manninen DL; Thompson TJ; Narayan V; Orians CE; Gregg EW; Eastman RC; Dasbach EJ; Herman WH; Newman JM; Narva AS; Ballard DJ; Engelgau MM
Pharmacoeconomics; 2004; 22(15):1015-27. PubMed ID: 15449965
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of a New Opportunistic Screening Strategy for Walk-in Fingertip HbA
Shono A; Kondo M; Hoshi SL; Okubo R; Yahagi N
Diabetes Care; 2018 Jun; 41(6):1218-1226. PubMed ID: 29686159
[TBL] [Abstract][Full Text] [Related]
9. A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus.
Chen TH; Yen MF; Tung TH
Diabetes Res Clin Pract; 2001 Nov; 54 Suppl 1():S37-42. PubMed ID: 11580967
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Three Doses of a Behavioral Intervention to Prevent or Delay Type 2 Diabetes in Rural Areas.
Radcliff TA; Côté MJ; Whittington MD; Daniels MJ; Bobroff LB; Janicke DM; Perri MG
J Acad Nutr Diet; 2020 Jul; 120(7):1163-1171. PubMed ID: 31899170
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
CDC Diabetes Cost-effectiveness Group
JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
[TBL] [Abstract][Full Text] [Related]
12. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
14. Screening for proteinuria in US adults: a cost-effectiveness analysis.
Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
[TBL] [Abstract][Full Text] [Related]
15. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis.
Kahn R; Alperin P; Eddy D; Borch-Johnsen K; Buse J; Feigelman J; Gregg E; Holman RR; Kirkman MS; Stern M; Tuomilehto J; Wareham NJ
Lancet; 2010 Apr; 375(9723):1365-74. PubMed ID: 20356621
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.
Hutton DW; Tan D; So SK; Brandeau ML
Ann Intern Med; 2007 Oct; 147(7):460-9. PubMed ID: 17909207
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
[TBL] [Abstract][Full Text] [Related]
18. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis.
Gillett M; Dallosso HM; Dixon S; Brennan A; Carey ME; Campbell MJ; Heller S; Khunti K; Skinner TC; Davies MJ
BMJ; 2010 Aug; 341():c4093. PubMed ID: 20729270
[TBL] [Abstract][Full Text] [Related]
19. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.
Samyshkin Y; Guillermin AL; Best JH; Brunell SC; Lloyd A
J Med Econ; 2012; 15 Suppl 2():6-13. PubMed ID: 22793669
[TBL] [Abstract][Full Text] [Related]
20. A cost analysis of community screening for diabetes in the central Wisconsin Medicare population (results from the MetaStar pilot project in Wausau).
Lee DS; Remington P; Madagame J; Blustein J
WMJ; 2000 Jun; 99(3):39-43. PubMed ID: 10927980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
